MiNK Therapeutics, Inc. (INKT)

Market Cap	28.76M
Revenue (ttm)	n/a
Net Income (ttm)	-10.78M
Shares Out	3.97M
EPS (ttm)	-2.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	7.83
Day's Range	n/a
52-Week Range	4.56 - 13.79
Beta	0.14
Analysts	Strong Buy
Price Target	37.50 (+415.82%)
Earnings Date	May 13, 2025

About INKT

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients wi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2021
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: INKT
• Website: https://minktherapeutics.com

Analyst Forecast

According to 2 analysts, the average rating for INKT stock is "Strong Buy." The 12-month stock price forecast is $37.5, which is an increase of 415.82% from the latest price.

Price Target

$37.5

(415.82% upside)

Analyst Consensus: Strong Buy